{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T07:53:47Z","timestamp":1760255627919,"version":"3.28.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11,11]]},"DOI":"10.7759\/cureus.73482","type":"journal-article","created":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T02:07:01Z","timestamp":1731377221000},"source":"Crossref","is-referenced-by-count":1,"title":["A Decade of Prevalence and Clinicopathological Insights Into Classical Hodgkin Lymphoma: A Study From an Indonesian Tertiary Hospital"],"prefix":"10.7759","author":[{"given":"Agnes  S","family":"Harahap","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefanny","family":"Charles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria  F","family":"Ham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-030-32482-7_1","article-title":"Epidemiology of Hodgkin Lymphoma","author":"Hjalgrim H","year":"2020","unstructured":"Hjalgrim H, Jarrett RF. Epidemiology of Hodgkin Lymphoma. Hematologic Malignancies. Engert A, Younes A (ed): Springer, Cham, Switzerland; 2020. 3-23. 10.1007\/978-3-030-32482-7_1"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-022-01281-9","article-title":"Incidence, mortality, risk factors, and trends for Hodgkin lymphoma: a global data analysis","volume":"15","author":"Huang J","year":"2022","unstructured":"Huang J, Pang WS, Lok V, et al.. Incidence, mortality, risk factors, and trends for Hodgkin lymphoma: a global data analysis. J Hematol Oncol. 2022, 15:57. 10.1186\/s13045-022-01281-9","journal-title":"J Hematol Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-013-0163-4","article-title":"Hodgkin lymphoma in pregnancy","volume":"8","author":"Bachanova V","year":"2013","unstructured":"Bachanova V, Connors JM. Hodgkin lymphoma in pregnancy. Curr Hematol Malig Rep. 2013, 8:211-7. 10.1007\/s11899-013-0163-4","journal-title":"Curr Hematol Malig Rep"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1182\/BLOOD.V95.4.1443.004K55_1443_1450","article-title":"Hodgkin and reed-sternberg cells represent an expansion of a single clone originating from a germinal center B-cell with functional immunoglobulin gene rearrangements but defective immunoglobulin transcription","volume":"95","author":"Marafioti T","year":"2000","unstructured":"Marafioti T, Hummel M, Foss HD, et al.. Hodgkin and reed-sternberg cells represent an expansion of a single clone originating from a germinal center B-cell with functional immunoglobulin gene rearrangements but defective immunoglobulin transcription. Blood. 2000, 95:1443-50. 10.1182\/BLOOD.V95.4.1443.004K55_1443_1450","journal-title":"Blood"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.11.8869","article-title":"Lymphocyte-predominant and classical Hodgkin's lymphoma: a comprehensive analysis from the German Hodgkin Study Group","volume":"26","author":"Nogov\u00e1 L","year":"2008","unstructured":"Nogov\u00e1 L, Reineke T, Brillant C, et al.. Lymphocyte-predominant and classical Hodgkin's lymphoma: a comprehensive analysis from the German Hodgkin Study Group. J Clin Oncol. 2008, 26:434-9. 10.1200\/JCO.2007.11.8869","journal-title":"J Clin Oncol"},{"key":"ref6","article-title":"Haematolymphoid Tumours","author":"WHO Classification of Tumours Editorial Board","year":"2024","unstructured":"WHO Classification of Tumours Editorial Board. Haematolymphoid Tumours. International Agency for Research on Cancer, Lyon, France; 2024."},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2006.1.253","article-title":"The management of patients with limited-stage classical Hodgkin lymphoma","author":"Gospodarowicz MK","year":"2006","unstructured":"Gospodarowicz MK, Meyer RM. The management of patients with limited-stage classical Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program. 2006, 253-8. 10.1182\/asheducation-2006.1.253","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"ref8","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.e19514","article-title":"Classical Hodgkin lymphoma: a surveillance, epidemiology, and end results (SEER) database analysis comparing racial and ethnic disparities with emphasis on Hispanics","volume":"41","author":"Toro-V\u00e9lez E","year":"2023","unstructured":"Toro-V\u00e9lez E, Velez-Mejia C, Rosas D, Kaur S, Liu Q, Michalek J, Diaz Duque AE. Classical Hodgkin lymphoma: a surveillance, epidemiology, and end results (SEER) database analysis comparing racial and ethnic disparities with emphasis on Hispanics. JCO. 2023, 41:19514.","journal-title":"JCO"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3889\/OAMJMS.2021.7304","article-title":"Disparity in the hospitals utilization among regions in Indonesia","volume":"9","author":"Mahmudiono T","year":"2021","unstructured":"Mahmudiono T, Laksono AD. Disparity in the hospitals utilization among regions in Indonesia. Maced J Med Sci. 2021, 9:1461-6. 10.3889\/OAMJMS.2021.7304","journal-title":"Maced J Med Sci"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-019-0799-1","article-title":"Global, regional, and national burden of Hodgkin lymphoma from 1990 to 2017: estimates from the 2017 Global Burden of Disease study","volume":"12","author":"Zhou L","year":"2019","unstructured":"Zhou L, Deng Y, Li N, et al.. Global, regional, and national burden of Hodgkin lymphoma from 1990 to 2017: estimates from the 2017 Global Burden of Disease study. J Hematol Oncol. 2019, 12:107. 10.1186\/s13045-019-0799-1","journal-title":"J Hematol Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.33948","article-title":"Global patterns of Hodgkin lymphoma incidence and mortality in 2020 and a prediction of the future burden in 2040","volume":"150","author":"Singh D","year":"2022","unstructured":"Singh D, Vaccarella S, Gini A, De Paula Silva N, Steliarova-Foucher E, Bray F. Global patterns of Hodgkin lymphoma incidence and mortality in 2020 and a prediction of the future burden in 2040. Int J Cancer. 2022, 150:1941-7. 10.1002\/ijc.33948","journal-title":"Int J Cancer"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.5772\/31746","article-title":"Epidemiology of Lymphoid Malignancy in Asia","author":"Mozaheb Z","year":"2012","unstructured":"Mozaheb Z. Epidemiology of Lymphoid Malignancy in Asia.  Epidemiology Insights. Da Cunha RDS (ed): InTech, Europe; 2012. 325-54. 10.5772\/31746"},{"key":"ref13","article-title":"Hodgkin Lymphoma in older patients","volume":"12","author":"Reagan PM","year":"2016","unstructured":"Reagan PM, Magnuson A, Friedberg JW. Hodgkin Lymphoma in older patients. AJHO. 2016, 12:13-9.","journal-title":"AJHO"},{"key":"ref14","doi-asserted-by":"crossref","DOI":"10.1007\/s11845-020-02418-w","article-title":"Elderly Hodgkin\u2019s lymphoma-a 10-year single-center experience","volume":"190","author":"Shakkak F","year":"2021","unstructured":"Shakkak F, Kumar S, Hennessy B, Elhassadi E. Elderly Hodgkin\u2019s lymphoma-a 10-year single-center experience. Ir J Med Sci. 2021, 190:1239-41.","journal-title":"Ir J Med Sci"},{"key":"ref15","article-title":"Hodgkin's lymphoma. An immunohistochemical profile in northern Iraq","volume":"35","author":"Fadhil MS","year":"2014","unstructured":"Fadhil MS, Al-Nueimy WM, Lazim AF. Hodgkin's lymphoma. An immunohistochemical profile in northern Iraq. Saudi Med J. 2014, 35:448-53.","journal-title":"Saudi Med J"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-97873-4_30","article-title":"Clinical Evaluation and Management of Hodgkin Lymphoma","author":"Ozuah NW","year":"2018","unstructured":"Ozuah NW, LaCasce AS. Clinical Evaluation and Management of Hodgkin Lymphoma. Concise Guide to Hematology. Lazarus H, Schmaier A (ed): Springer, Cham, Switzerland; 2018. 371-8. 10.1007\/978-3-319-97873-4_30"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2012.07.002","article-title":"Hodgkin lymphoma","volume":"85","author":"Gobbi PG","year":"2013","unstructured":"Gobbi PG, Ferreri AJ, Ponzoni M, Levis A. Hodgkin lymphoma. Crit Rev Oncol Hematol. 2013, 85:216-37. 10.1016\/j.critrevonc.2012.07.002","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.30525\/978-9934-588-53-2-49","article-title":"X-ray Tomographic Picture of Hodgkin\u2019s Disease","author":"Sokolov V","year":"2020","unstructured":"Sokolov V, Korsun A. X-ray Tomographic Picture of Hodgkin\u2019s Disease. Theoretical and Practical Aspects of the Development of the European Research Area. Baltija Publishing , Latvia, Europe; 2020. 120-44. 10.30525\/978-9934-588-53-2-49"},{"key":"ref19","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14194893","article-title":"Histological subtypes drive distinct prognostic immune signatures in classical Hodgkin lymphoma","volume":"14","author":"Lamaison C","year":"2022","unstructured":"Lamaison C, Ferrant J, Gravelle P, et al.. Histological subtypes drive distinct prognostic immune signatures in classical Hodgkin lymphoma. Cancers. 2022, 14:4893.","journal-title":"Cancers"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14112647","article-title":"An update on the pathology and molecular features of Hodgkin lymphoma","volume":"14","author":"Satou A","year":"2022","unstructured":"Satou A, Takahara T, Nakamura S. An update on the pathology and molecular features of Hodgkin lymphoma. Cancers (Basel). 2022, 14:2647. 10.3390\/cancers14112647","journal-title":"Cancers (Basel)"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdj037","article-title":"Lymphocyte-rich classical Hodgkin lymphoma (LRCHL): clinico-pathological characteristics and outcome of a rare entity","volume":"17","author":"de Jong D","year":"2006","unstructured":"de Jong D, Bosq J, MacLennan KA, et al.. Lymphocyte-rich classical Hodgkin lymphoma (LRCHL): clinico-pathological characteristics and outcome of a rare entity. Ann Oncol. 2006, 17:141-5. 10.1093\/annonc\/mdj037","journal-title":"Ann Oncol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.9790\/0853-0603032326","article-title":"Clinicopathological profile of Hodgkin lymphoma in tertiary care hospital","volume":"6","author":"Geetha DRP","year":"2017","unstructured":"Geetha DRP. Clinicopathological profile of Hodgkin lymphoma in tertiary care hospital. IOSR Journal of Dental and Medical Sciences. 2017, 6:23-6. 10.9790\/0853-0603032326","journal-title":"IOSR Journal of Dental and Medical Sciences"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.14670\/HH-18-644","article-title":"Optimizing assessment of CD30 expression in Hodgkin lymphoma by controlling for low expression","volume":"39","author":"Sarwar S","year":"2024","unstructured":"Sarwar S, Tome ME, Billheimer D, Spier C, Smith CL, Persky D, Schmelz M. Optimizing assessment of CD30 expression in Hodgkin lymphoma by controlling for low expression. Histol Histopathol. 2024, 39:319-31. 10.14670\/HH-18-644","journal-title":"Histol Histopathol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1111\/his.12914","article-title":"Expression of CD30 as a biomarker to predict response to brentuximab vedotin","volume":"69","author":"Xu ML","year":"2016","unstructured":"Xu ML, Acevedo-Gadea C, Seropian S, Katz SG. Expression of CD30 as a biomarker to predict response to brentuximab vedotin. Histopathology. 2016, 69:155-8. 10.1111\/his.12914","journal-title":"Histopathology"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.26717\/BJSTR.2018.03.000912","article-title":"The CD15 immunohistochemical marker of Hodgkin Reed-Sternberg cells a perspective","volume":"3","author":"Benharroch D","year":"2018","unstructured":"Benharroch D, Zarin P, Nalbandyan K. The CD15 immunohistochemical marker of Hodgkin Reed-Sternberg cells a perspective. Biomed J Sci Tech Res. 2018, 3:1-2. 10.26717\/BJSTR.2018.03.000912","journal-title":"Biomed J Sci Tech Res"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(22)01481-1","article-title":"HL-443 Expression of CD20 in classical Hodgkin lymphoma and its relationship with CD30, CD15 markers","volume":"1016","author":"Mosesyan I","year":"2022","unstructured":"Mosesyan I, Saaryan M. HL-443 Expression of CD20 in classical Hodgkin lymphoma and its relationship with CD30, CD15 markers. Clin Lymphoma Myeloma Leuk. 2022, 1016:2152-650. 10.1016\/S2152-2650(22)01481-1","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.7150\/jca.13107","article-title":"CD20 over-expression in Hodgkin Reed-Sternberg cells of classical Hodgkin lymphoma: the neglected quest","volume":"6","author":"Benharroch D","year":"2015","unstructured":"Benharroch D, Nalbandyan K, Lazarev I. CD20 over-expression in Hodgkin Reed-Sternberg cells of classical Hodgkin lymphoma: the neglected quest. J Cancer. 2015, 6:1155-9. 10.7150\/jca.13107","journal-title":"J Cancer"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-010-0052-z","article-title":"Does rituximab have a place in treating classic hodgkin lymphoma?","volume":"5","author":"Oki Y","year":"2010","unstructured":"Oki Y, Younes A. Does rituximab have a place in treating classic hodgkin lymphoma?. Curr Hematol Malig Rep. 2010, 5:135-9. 10.1007\/s11899-010-0052-z","journal-title":"Curr Hematol Malig Rep"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.993768","article-title":"CD20 expression is closely associated with Epstein-Barr virus infection and an inferior survival in nodular sclerosis classical Hodgkin lymphoma","volume":"12","author":"Zhao X","year":"2022","unstructured":"Zhao X, Ma Y, Bian H, Liu Z. CD20 expression is closely associated with Epstein-Barr virus infection and an inferior survival in nodular sclerosis classical Hodgkin lymphoma. Front Oncol. 2022, 12:993768. 10.3389\/fonc.2022.993768","journal-title":"Front Oncol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2014.951849","article-title":"High CD20+ background cells predict a favorable outcome in classical Hodgkin lymphoma and antagonize CD68+ macrophages","volume":"56","author":"Panico L","year":"2015","unstructured":"Panico L, Tenneriello V, Ronconi F, et al.. High CD20+ background cells predict a favorable outcome in classical Hodgkin lymphoma and antagonize CD68+ macrophages. Leuk Lymphoma. 2015, 56:1636-42. 10.3109\/10428194.2014.951849","journal-title":"Leuk Lymphoma"},{"key":"ref31","article-title":"CD30, CD15, CD50, and PAX5 expressions as diagnostic markers for Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (sALCL)","volume":"50","author":"Ranuhardy D","year":"2018","unstructured":"Ranuhardy D, Suzanna E, Sari RM, Hadisantoso DW, Andalucia R, Abdillah A. CD30, CD15, CD50, and PAX5 expressions as diagnostic markers for Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (sALCL). Acta Med Indones. 2018, 50:104-9.","journal-title":"Acta Med Indones"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1002\/jha2.426","article-title":"First-line treatment of stage IIB to stage IV classical Hodgkin lymphoma in Italy, Israel, and Spain: Patient characteristics, treatment patterns, and clinical outcomes","volume":"3","author":"Avigdor A","year":"2022","unstructured":"Avigdor A, Trinchese F, Gavini F, et al.. First-line treatment of stage IIB to stage IV classical Hodgkin lymphoma in Italy, Israel, and Spain: Patient characteristics, treatment patterns, and clinical outcomes. EJHaem. 2022, 3:415-25. 10.1002\/jha2.426","journal-title":"EJHaem"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.799948","article-title":"Real-world outcomes of Hodgkin lymphoma: a multi-centric registry from India","volume":"11","author":"Bhurani D","year":"2021","unstructured":"Bhurani D, Nair R, Rajappa S, et al.. Real-world outcomes of Hodgkin lymphoma: a multi-centric registry from India. Front Oncol. 2021, 11:799948. 10.3389\/fonc.2021.799948","journal-title":"Front Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/310671-a-decade-of-prevalence-and-clinicopathological-insights-into-classical-hodgkin-lymphoma-a-study-from-an-indonesian-tertiary-hospital","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T02:07:04Z","timestamp":1731377224000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/310671-a-decade-of-prevalence-and-clinicopathological-insights-into-classical-hodgkin-lymphoma-a-study-from-an-indonesian-tertiary-hospital"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,11]]},"references-count":33,"URL":"https:\/\/doi.org\/10.7759\/cureus.73482","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11,11]]}}}